A Phase 1 interventional study of CP-690,550 (tofacitinib) and Methotrexate (MTX) in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-02-04.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 39th largest by enrollment, is one of 2 that started in 2005, is one of 6 in phase 1, and was the 20th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 80th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2005, is one of 23 in phase 1, and was the 106th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was designed to estimate the effects of methotrexate (MTX) on the pharmacokinetics (PK) of CP-690,550 when administered to subjects with rheumatoid arthritis (RA), to estimate the effects of CP-690,550 on the PK of MTX and to evaluate the short-term safety and tolerability of co-administration of CP-690,550 and MTX.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h
Drug: CP-690,550 (tofacitinib) · Drug: Methotrexate (MTX)
CP-690,550 30 mg q12h for 5 days
individual dose of methotrexate (stably dosed)
Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550
AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Maximum Observed Plasma Concentration (Cmax) for CP-690,550
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post-dose on Day 1 and Day 7
Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX)
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,12, 24 and 48 hours post-dose on Day 1 and Day 7
Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Plasma Decay Half-Life (t1/2) for CP-690,550
Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Apparent Oral Clearance (CL/F) for CP-690,550
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 8 and 12 hours post-dose on Day 6 and Day 7
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX)
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 ,12, 24 and 48 hours post-dose on Day 1 and Day 7
Plasma Decay Half-Life (t1/2) for Methotrexate (MTX)
Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7
Apparent Oral Clearance (CL/F) for Methotrexate (MTX)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: 0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 , 12, 24 and 48 hours post-dose on Day 1 and Day 7
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550
Time frame: 0 (pre-dose) through 12 hours post-dose on Day 6 and Day 7
Renal Clearance (CL R) for CP-690,550
Time frame: 0 (pre-dose) through 24 hours post-dose on Day 6 and Day 7
Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX)
Time frame: 0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7
Renal Clearance (CL R) for Methotrexate (MTX)
Time frame: 0 (pre-dose) through 24 hours post-dose on Day 1 and Day 7
| Milestone | Methotrexate + CP-690,550 |
|---|---|
| Started | 12 |
| Completed | 12 |
| Not completed | 0 |
AUC (0-12)= area under the plasma concentration time-curve from time zero (pre-dose) to 12 hours (0-12).
| nanogram*hour/milliliter (ng*hr/mL) | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)] for CP-690,550 | 1370 ± 423 | 1410 ± 425 |
| ng/mL | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for CP-690,550 | 375 ± 91.6 | 384 ± 84.8 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
| ng*hr/mL | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Methotrexate (MTX) | 1850 ± 685 | 1720 ± 753 |
| ng/mL | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Methotrexate (MTX) | 478 ± 106 | 433 ± 175 |
| hour | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) for CP-690,550 | 1.00 (0.50 to 1.00) | 1.00 (0.50 to 1.00) |
Plasma decay half-life is the time measured for the plasma concentration of CP-690,550 to decrease by one half.
| hour | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Plasma Decay Half-Life (t1/2) for CP-690,550 | 2.64 ± 0.356 | 3.12 ± 0.74 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| mL/hr | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Apparent Oral Clearance (CL/F) for CP-690,550 | 23200 ± 8380 | 23511 ± 8784 |
| hour | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) for Methotrexate (MTX) | 1.00 (0.50 to 1.50) | 1.25 (0.50 to 2.00) |
Plasma decay half-life is the time measured for the plasma concentration of MTX to decrease by one half.
| hour | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Plasma Decay Half-Life (t1/2) for Methotrexate (MTX) | 2.87 ± 0.962 | 3.36 ± 1.13 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population PK modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| mL/hr | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Apparent Oral Clearance (CL/F) for Methotrexate (MTX) | 9890 ± 3370 | 11500 ± 5430 |
| milligram | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 12 Hours (Ae[0-12]) for CP-690,550 | 6.65 ± 2.26 | 6.58 ± 2.34 |
| litre/hour (L/hr) | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|
| Renal Clearance (CL R) for CP-690,550 | 5490 ± 2890 | 5240 ± 2630 |
| milligram | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Total Amount of Unchanged Drug Excreted in the Urine From Time Zero to 24 Hours (Ae[0-24]) for Methotrexate (MTX) | 18.1 ± 9.31 | 13.2 ± 4.38 |
| L/hr | Methotrexate | Methotrexate + CP-690,500 |
|---|---|---|
| Renal Clearance (CL R) for Methotrexate (MTX) | 10.2 ± 4.56 | 8.95 ± 4.64 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Methotrexate | — | 0/12 (0%) | 5/12 (41.7%) |
| CP-690,500 | — | 0/12 (0%) | 6/12 (50%) |
| Methotrexate + CP-690,500 | — | 0/12 (0%) | 5/12 (41.7%) |
| Event | Methotrexate | CP-690,500 | Methotrexate + CP-690,500 |
|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 0/12 | 0/12 | 2/12 |
| NauseaGastrointestinal disorders | 0/12 | 2/12 | 1/12 |
| HeadacheNervous system disorders | 2/12 | 1/12 | 0/12 |
| SinusitisInfections and infestations | 1/12 | 1/12 | 1/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/12 | 1/12 | 1/12 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 1/12 | 1/12 |
| Muscle fatigueMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 0/12 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/12 | 1/12 | 1/12 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 1/12 | 0/12 | 0/12 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/12 | 1/12 | 1/12 |
| Age Continuous(years) | Methotrexate + CP-690,550 |
|---|---|
| Mean | 57.3 ± 10.2 |
| Sex: Female, Male(Participants) | Methotrexate + CP-690,550 |
|---|---|
| Female | 8 |
| Male | 4 |
The record gives a start of Apr 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 6 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib